BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines external Cost of Development Programs ($M) ($M)
Form 10-Q / 10-K MD&A R&D Expense Summary Table
Latest, Q2 2026
194
Period ended Jun 30, 2026
Change on a year earlier
+6.3%
183 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
22
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up external cost of development programs ($m)
- External R&D — BRUKINSA (zanubrutinib, BTKi) ($M)–
- External R&D — TEVIMBRA (tislelizumab, Anti-PD-1) ($M)–
- External R&D — BEQALZI / Sonrotoclax (BGB-11417, BCL2 Inhibitor) ($M)–
- External R&D — Tacabrutideg (BGB-16673, BTK CDAC) ($M)–
- External R&D — BGB-43395 (CDK4 Inhibitor) ($M)–
- External R&D — PARTRUVIX (pamiparib, PARP Inhibitor) ($M, FY17–FY23)–
- External R&D — Ociperlimab (BGB-A1217, Anti-TIGIT) ($M, FY20–FY23)–
- External R&D — BGB-A445 (Anti-OX40 Agonist) ($M, FY20–FY23)–
- External R&D — Other Internal Clinical & Preclinical Projects ($M)–
- External R&D — R&D Collaboration Projects ($M)–
Cite this data
StockData. (2026). BeOne Medicines External Cost of Development Programs ($M) ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd_ext_dev_programs
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.